Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lymphatic filariasis

    Prescrire International
    |April 4, 2008
    PubMed
    Summary
    This summary is machine-generated.

    Lymphatic filariasis, a disabling tropical disease, is treated with diethylcarbamazine. Ivermectin offers an alternative for specific patient groups, improving treatment options for parasitic infections.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Patients want to be heard.

    Prescrire international·2019
    Same journal

    Prescrire's Médicaments en Questions: First results of a practice improvement programme.

    Prescrire international·2019
    Same journal

    Pneumococcal vaccination in persons at high risk.

    Prescrire international·2019
    Same journal

    Resectable non-small cell lung cancer Adjuvant chemotherapy: slightly longer survival.

    Prescrire international·2019
    Same journal

    Diethylstilbestrol (DES): also harms the third generation.

    Prescrire international·2019
    Same journal

    Cometinib (Cotellic°) and metastic melanoma.

    Prescrire international·2019
    See all related articles

    Area of Science:

    • Tropical medicine
    • Parasitology
    • Infectious diseases

    Background:

    • Lymphatic filariasis is a disabling parasitic disease prevalent in tropical and subtropical areas.
    • Current standard treatment for adults involves oral diethylcarbamazine.
    • Alternative treatments are needed, particularly for co-infected patients.

    Purpose of the Study:

    • To review the efficacy and safety of diethylcarbamazine and ivermectin for lymphatic filariasis.
    • To identify alternative treatment strategies for lymphatic filariasis.

    Main Methods:

    • Literature review of existing studies on lymphatic filariasis treatment.
    • Analysis of drug efficacy and patient outcomes.

    Main Results:

    • Diethylcarbamazine is the primary oral antiparasitic drug for adults.
    • Ivermectin serves as an effective alternative, particularly for individuals with co-existing onchocerciasis or loiasis.

    Conclusions:

    • Diethylcarbamazine remains the standard treatment for lymphatic filariasis.
    • Ivermectin provides a valuable alternative, expanding therapeutic options for parasitic diseases.